On February 18, 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, reported that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat chemotherapy drug resistance and cachexia (Press release, Kairos Pharma, FEB 18, 2025, View Source [SID1234650354]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This funding will accelerate the Company’s research efforts to develop ENV205, a first-in-class therapy designed to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. By targeting key pathways that drive cachexia, Kairos seeks to develop ENV205 to provide a much-needed solution to help patients maintain their health and resilience throughout cancer therapy. The Company has long been partnering with Cedars-Sinai in its research and development of ENV205.
Neil Bhowmick, Kairos Pharma’s Chief Scientific Officer, stated, "We are grateful to our supporters and collaborators who share our vision of improving outcomes for cancer patients worldwide. We look forward to collaborating with the Department of Defense to advance this promising new therapy toward clinical trials."
Dr. John Yu, Kairos Pharma’s Chief Executive Officer, added, "Developing our therapeutics through non-dilutive federal funding has been a hallmark of Kairos’s success in drug development and underscores the excellence of our scientific team."
Cachexia is a severe muscle-wasting condition that affects over half of cancer patients and significantly impacts quality of life, treatment tolerance, and survival. It is a complex metabolic syndrome characterized by involuntary weight loss, muscle atrophy, and systemic inflammation, which currently lacks effective treatment options.